Seeking Alpha

Shares of Exelixis (EXEL) gain 20% premarket after the firm announces positive top-line results...

Shares of Exelixis (EXEL) gain 20% premarket after the firm announces positive top-line results from its Phase 3 clinical trail of cabozantinib in patients with medullary thyroid cancer. The company aims to build a cabozantinib franchise that includes large indications such as prostate cancer.
Comments (1)
  • TruffelPig
    , contributor
    Comments (4059) | Send Message
     
    This is a real winner. That stuff also seems to work against bone metastasis! Looks like multi billion dollar potential. Also, EXEL was trading with a 50% discount until this morning - still time to jump in I think. I am just too happy about the puts I sold :).

     

    Long EXEL :) (stocks and puts sold)
    24 Oct 2011, 09:24 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|